RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

OT: CYPB
That's a good summary of the CC. The CC didnt mention the fact that the BioLine trial was done almost entirely in India and Romania, with just a handful of US patients, which would argue for a PhIIb with a more representative patient population.

The sales force question is open to debate: It's absolutely correct that CYPB emphasized their belief that a small sales force can in theory access the psychiatrists who do the bulk of antipsychotic prescribing, but keeping that sales force intact while trying to get BL-1020 through clinical testing without it being a drag on earnings is tough. They hope they can inlicense a marketed drug or copromote something, which is hardly a new idea--particularly the former. To get something good means spending down a considerable amount of their cash. I personally hope that they monetize the Savella stream, such as it is.

NeuroInvestment